This supplement to The American Journal of Managed Care contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.

Faculty

Disclosure Statement

It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants have declared the following affiliations with corporate organizations:

• David J. Harrison, PhD
  Employee:
  • Pfizer Inc
• Robin P. Hertz, PhD
  Employee:
  • Pfizer Inc
• Amie T. Joyce, MPH
  Research Support:
  • Pfizer Inc
• Antony D. Loebel, MD
  Employee:
  • Pfizer Inc
• Michael B. Lustik, MS
  Contractor:
  • Pfizer Inc
• Margaret McDonald, PhD
  Employee:
  • Pfizer Inc
• Daniel A. Ollendorf, MPH
  Research Support:
  • Pfizer Inc
• George M. Simpson, MD
  Consultant:
  • Janssen
  • Pfizer
  Research Support:
  • AstraZeneca
  • GlaxoSmithKline
  • Janssen
  • Pfizer
• Richard C. Surles, PhD
  Adviser:
  • Eli Lilly and Company
• Alan N. Unger, PhD
  Contractor:
  • Pfizer Inc

Signed disclosures are on file at the offices of The American Journal of Managed Care, Jamesburg, New Jersey.

This supplement was funded by Pfizer Inc.

Acknowledgments

We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.